Current issues in malignant pleural mesothelioma evaluation and management

Oncologist

Volumn 19, Issue 9, 2014, Pages 975-984

  Jing, Ai ^a   Stevenson, James P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Asbestos adverse effects; Clinical trials; Mesothelioma; Pleural neoplasms; Review

Indexed keywords

AMATUXIMAB; ANTINEOPLASTIC AGENT; APITOLISIB; BEVACIZUMAB; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CEDIRANIB; CISPALTIN; CISPLATIN; CRS 207; CYANOCOBALAMIN; DEFACTINIB; DOCETAXEL; FOLIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GSK 2256098; LY 3023414; MONTANIDE; NAVELBINE; NINTEDANIB; OXALIPLATIN; PEMETREXED; PLACEBO; RALTITREXED; SS1P; TICILIMUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VORINOSTAT; VS 5584; WT1 VACCINE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LUNG RESECTION; META ANALYSIS (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PLEURECTOMY; QUALITY OF LIFE; RADIATION DOSE; RISK FACTOR; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PLEURA; PROGNOSIS; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURA; PNEUMONECTOMY; PROGNOSIS; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 84906973891     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0122     Document Type: Article

References (121)

1. Previous version: SEER Cancer Statistics Review, 1975-2010. Available at http://seer.cancer.gov/csr/ 1975_2010/. Updated June 14, 2013.
2. Robinson BM. Malignant pleural mesothelioma: An epidemiological perspective. Ann Cardiothorac Surg 2012;1:491-496.
3. Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993;103 (suppl):373S-376S.
4. Tan E, Warren N, Darnton AJ et al. Projection of mesothelioma mortality in Britain using bayesian methods. Br J Cancer 2010;103:430-436.
5. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980;46:2736-2740.
6. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34:718-721.
7. Hansen J, deKlerk NH, Musk AW et al.Environmental exposure to crocidolite and mesothelioma: Exposure-response relationships. Am J Respir Crit Care Med 1998;157:69-75.
8. Metintas S, Metintas M, Ucgun I et al. Malignant mesothelioma due to environmental exposure to asbestos: Follow-up of a Turkish cohort living in a rural area. Chest 2002;122:2224-2229.
9. Pan XL, Day HW, Wang W et al. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 2005;172:1019-1025.
10. Gulmez I, Kart L, Buyukoglan H et al. Evaluation of malignant mesothelioma in central Anatolia: A study of 67 cases. Can Respir J 2004;11:287-290.
11. Tward JD, Wendland MM, Shrieve DC et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006;107:108-115.
12. Teta MJ, Lau E, Sceurman BK et al. Therapeutic radiation for lymphoma: Risk of malignant mesothelioma. Cancer 2007;109:1432-1438.
13. Gibb H, Fulcher K, Nagarajan S et al. Analyses of radiation and mesothelioma in the US Transuranium and Uranium Registries. Am J Public Health 2013; 103:710-716.
14. Comar M, Zanotta N, Pesel G et al. Asbestos and SV40 in malignant pleural mesothelioma from a hyperendemic area of north-eastern Italy. Tumori 2012;98:210-214.
15. Cristaudo A, Foddis R, Vivaldi A et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: A molecular epidemiologic case-control study. Cancer Res 2005; 65:3049-3052.
16. Lundstig A, Dejmek A, Eklund C et al. No detection of SV40 DNA in mesothelioma tissues from a high incidence area in Sweden. Anticancer Res 2007;27:4159-4161.
17. Manfredi JJ, Dong J, Liu WJ et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res 2005;65:2602-2609.
18. Carbone M, Ferris LK, Baumann F et al. BAP1 cancer syndrome: Malignant mesothelioma, uveal andcutaneousmelanoma, and MBAITs. J Transl Med 2012;10:179.
19. Carbone M, Yang H, Pass HI et al. BAP1 and cancer. Nat Rev Cancer 2013;13:153-159.
20. Testa JR, Cheung M, Pei J et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-1025.
21. Bott M, Brevet M, Taylor BS et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011;43:668-672.
22. Boutin C, Rey F, Gouvernet J et al. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 1993;72:394-404.
23. Edwards JG, Abrams KR, Leverment JN et al. Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems. Thorax 2000;55: 731-735.
24. Kadota K, Suzuki K, Sima CS et al. Pleomorphic epithelioiddiffusemalignant pleural mesothelioma: Aclinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol 2011;6:896-904.
25. Suzuki K, Kadota K, Sima CS et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother 2011;60:1721-1728.
26. Miettinen M, Limon J, Niezabitowski A et al. Calretinin and other mesothelioma markers in synovial sarcoma: Analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol 2001;25:610-617.
27. Creaney J, Christansen H, Lake R et al. Soluble mesothelin related protein in mesothelioma. J Thorac Oncol 2006;1:172-174.
28. Schneider J, Hoffmann H, Dienemann H et al. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008;3:1317-1324.
29. Rai AJ, Flores RM, Mathew A et al. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: Analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med 2010;48:271-278.
30. Pass HI, Levin SM, Harbut MR et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012;367:1417-1427.
31. Plathow C, Staab A, Schmaehl A et al. Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: Initial results. Invest Radiol 2008;43:737-744.
32. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005;49(suppl 1):S27-S32.
33. Srensen JB, Ravn J, Loft A et al. Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy comparedtopathological findingsafter extrapleural pneumonectomy. Eur J Cardiothorac Surg 2008;34: 1090-1096.
34. Wilcox BE, Subramaniam RM, Peller PJ et al. Utility of integrated computed tomographypositron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer 2009;10:244-248.
35. Rusch VW, Giroux D. Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg 2012;1:438-448.
36. Rusch VW, Giroux D, Kennedy C et al. Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database. J Thorac Oncol 2012;7:1631-1639.
37. Hiddinga BI, van Meerbeeck JP. Surgery in mesothelioma—where do we go after MARS? J Thorac Oncol 2013;8:525-529.
38. Treasure T, Waller D, Tan C et al. The Mesothelioma and Radical Surgery randomized controlled trial: The MARS feasibility study. J Thorac Oncol 2009;4:1254-1258.
39. Treasure T, Lang-Lazdunski L, Waller D et al. Extra-pleural pneumonectomy versus no extrapleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12: 763-772.
40. Zahid I, Sharif S, Routledge T et al. Is pleurectomyanddecorticationsuperior topalliative care in the treatment of malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 2011;12: 812-817.
41. Teh E, Fiorentino F, Tan C et al. A systematic review of lung-sparing extirpative surgery for pleural mesothelioma. J R Soc Med 2011;104: 69-80.
42. Rice D, Rusch V, Pass H etal. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: A consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. J Thorac Oncol 2011;6:1304-1312.
43. Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy versus pleurectomy/ decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. J Thorac Cardiovasc Surg 2008;135: 620-626, 626.e1-626.e3.
44. Lang-Lazdunski L, Bille A, Lal R et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 2012;7:737-743.
45. Flores RM, Krug LM, Rosenzweig KE et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: A phase II trial. J Thorac Oncol 2006;1:289-295.
46. Krug LM, Pass HI, Rusch VW et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-3013.
47. Weder W, Stahel RA, Bernhard J et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:1196-1202.
48. Rusch VW, Rosenzweig K, Venkatraman E et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-795.
49. Rice DC, Stevens CW, Correa AM et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007; 84:1685-1692; discussion 1692-1693.
50. Cho BC, Feld R, Leighl N et al. A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” approach for resectable malignant pleural mesothelioma. J Thorac Oncol 2014;9:397-402.
51. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experiencein10years. Eur J Cardiothorac Surg2002; 22:298-305.
52. Tilleman TR, Richards WG, Zellos L et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: A phase II prospective study. J Thorac Cardiovasc Surg 2009;138: 405-411.
53. Sugarbaker DJ, Gill RR, Yeap BY et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg 2013;145: 955-963.
54. Friedberg JS, Mick R, Culligan M et al. Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma. Ann Thorac Surg 2011;91:1738-1745.
55. Friedberg JS, Culligan MJ, Mick R et al. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg 2012;93:1658-1665; discussion 1665- 1667.
56. Fennell DA, Gaudino G, O’Byrne KJ et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5: 136-147.
57. Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: A systematic review of the literaturewith meta-analysis. Lung Cancer 2002; 38:111-121.
58. Ellis P, Davies AM, Evans WK et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and practice guideline. J Thorac Oncol 2006;1:591-601.
59. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644.
60. van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23: 6881-6889.
61. Ceresoli GL, Zucali PA, Gianoncelli L et al. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010;36:24-32.
62. Manegold C, Symanowski J, Gatzemeier U et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005;16:923-927.
63. Jassem J, Ramlau R, Santoro A et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698-1704.
64. Zucali PA, Perrino M, Lorenzi E et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. LungCancer 2014; 84:265-270.
65. Zucali PA, Ceresoli GL, Garassino I et al. Gemcitabine and vinorelbine in pemetrexedpretreated patients with malignant pleural mesothelioma. Cancer 2008;112:1555-1561.
66. Xanthopoulos A, Bauer TT, Blum TG et al. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: An observational study. J Occup Med Toxicol 2008;3:34.
67. Toyokawa G, Takenoyama M, Hirai F et al. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol 2013 [Epub ahead of print].
68. Ceresoli GL, Zucali PA, De Vincenzo F et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011;72:73-77.
69. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: Targeting chromatin modifications. Mol Cancer Ther 2009;8:1409-1420.
70. Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: Preclinical rationale and clinical trials. J Thorac Oncol 2010;5: 275-279.
71. Krug LM, Curley T, Schwartz L et al. Potential role of histone deacetylase inhibitors in mesothelioma: Clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006;7:257-261.
72. Krug LM, Kindler H, Calvert H et al. VANTAGE 014: Vorinostat (V) in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: A phase III, randomized, double-blind, placebo-controlled trial. Eur J Cancer 2011;47:2-3.
73. Remon J, Lianes P, Martnez S et al., Malignant mesothelioma: New insights into a rare disease. Cancer Treat Rev 2013;39:584-591.
74. Kindler HL, Karrison TG, Gandara DR et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012;30:2509-2515.
75. Dowell JE, Dunphy FR, Taub RN et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 2012;77:567-571.
76. Zalcman G, Margery J, Scherpereel A et al. IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J Clin Oncol 2010;28(suppl): 7020a.
77. Zalcman G, Mazieres J, Scherpereel A et al. IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma (MPM). J Clin Oncol 2012;30 (suppl):TPS7112a.
78. Hilberg F, Roth GJ, Krssak M et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-4782.
79. Mross K, Stefanic M, Gmehling D et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311-319.
80. Reck M, Kaiser R, Mellemgaard A et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated nonsmall-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143-155.
81. McClatchey AI, Fehon RG. Merlin and the ERM proteins—regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol 2009;19: 198-206.
82. Bianchi AB, Mitsunaga SI, Cheng JQ et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995;92: 10854-10858.
83. Sekido Y, Pass HI, Bader S et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55:1227-1231.
84. Poulikakos PI, Xiao GH, Gallagher R et al. Reexpression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006;25: 5960-5968.
85. Soria J-C, Gan HK, Arkenau H-T et al. Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors. J Clin Oncol 2012;30 (suppl):3000a.
86. Katso R, Okkenhaug K, Ahmadi K et al. Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001;17:615-675.
87. Ramos-Nino ME, Vianale G, Sabo-Attwood T et al. Human mesothelioma cells exhibit tumor cell specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol Cancer Ther 2005;4:835-842.
88. de Assis LV, Locatelli J, Isoldi MC.The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma. Biochim Biophys Acta 2014;1845:232-247.
89. James MF, Han S, Polizzano C et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 2009;29:4250-4261.
90. López-Lago MA, Okada T, Murillo MM et al. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009;29:4235-4249.
91. Garland LL, Ou S-H, Moon J et al.SWOG0722:A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM). J Clin Oncol 2012;30(suppl):7083a.
92. Wallin JJ, Edgar KA, Guan J et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011;10:2426-2436.
93. Dolly S, Krug LM, Wagner AJ. et al. Evaluation of tolerability and anti-tumor activity of GDC-0980, an oral PI3K/mTOR inhibitor, administrated to patients with advanced malignant pleural mesothelioma (MPM). Presented at: International Association for the Study of Lung Cancer 15th World Conference on Lung Cancer; October 27-31, 2013; Sydney, Australia.
94. Grégoire M. What’s the place of immunotherapy in malignant mesothelioma treatments? Cell Adhes Migr 2010;4:153-161.
95. Meloni F, Morosini M, Solari N et al. Foxp3 expressing CD41 CD251 and CD81CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006;67:1-12.
96. Solinas G, Germano G, Mantovani A et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009;86:1065-1073.
97. Bograd AJ, Suzuki K, Vertes E et al. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 2011;60:1509-1527.
98. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-140.
99. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53.
100. Servais EL, Colovos C, Rodriguez L et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res 2012;18: 2478-2489.
101. Hassan R, Cohen SJ, Phillips M et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 2010;16:6132-6138.
102. Hassan R, Jahan TM, Kindler HL et al. Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial. J Clin Oncol 2012;30(suppl):7030a.
103. Li Q, Verschraegen CF, Mendoza J et al. Cytotoxic activity of the recombinant antimesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res 2004;24:1327-1335.
104. Hassan R, Bullock S, Premkumar A et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus i.v. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-5149.
105. Hassan R, Miller AC, Sharon E et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 2013;5:208ra147.
106. Le DT, Brockstedt DG, Nir-Paz R et al. A liveattenuated Listeria vaccine (ANZ-100) and a liveattenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clin Cancer Res 2012; 18:858-868.
107. Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012;13:e301-e310.
108. Krug LM, Dao T, Brown AB et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and nonsmall cell lung cancer. Cancer Immunol Immunother 2010;59:1467-1479.
109. Krug L, Tsao AS, Kass S et al. Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM). J Clin Oncol 2011;29(suppl):TPS139a.
110. Dao T, Yan S, Veomett N et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013;5: 176ra33.
111. Akhurst RJ, Hata A. Targeting the TGFb signalling pathway in disease. Nat Rev Drug Discov 2012;11:790-811.
112. Massagué J. TGFbeta in Cancer. Cell 2008; 134:215-230.
113. Kumar-Singh S, Weyler J, Martin MJ et al. Angiogenic cytokines in mesothelioma: A study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 1999;189:72-78.
114. DeLong P, Carroll RG, Henry AC et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 2005;4:342-346.
115. Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF-b in cancer patients. Curr Pharm Biotechnol 2011;12:2176-2189.
116. Stevenson JP, Kindler HL, Papasavvas E et al. Immunological effects of the TGFb-blocking antibody GC1008 in malignant pleural mesothelioma patients. OncoImmunology 2013;2:e26218.
117. Sterman DH, Haas A, Moon E et al. A trial of intrapleural adenoviral-mediated Interferon-a2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011;184:1395-1399.
118. Sterman D, Alley E, Recio A et al. A pilot and feasibility trial evaluating two different chemotherapy regimens in combination with intrapleural adenoviral-mediated interferon-alpha (SCH 721015, Ad.hIFN-alpha2b) gene transfer for malignant pleural mesothelioma [abstract]. Presented at: International Association for the Study of Lung Cancer 15th World Conference on Lung Cancer; October 27-31, 2013; Sydney, Australia.
119. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565-1570.
120. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: An overview of preclinical and translational research. Cancer Immun 2013; 13:5.
121. Calabr L, Morra A, Fonsatti E et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial. Lancet Oncol 2013;14: 1104-1111.